Market Research Logo

Biogen, Inc. - Product Pipeline Review - 2016

Biogen, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Biogen, Inc. - Product Pipeline Review - 2016’, provides an overview of the Biogen, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Biogen, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Biogen, Inc.
The report provides overview of Biogen, Inc. including its business description, key facts, and locations and subsidiaries
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report assesses Biogen, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report features Biogen, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Biogen, Inc.’s strategic position with total access to detailed information on its product pipeline
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Biogen, Inc.
Identify potential new clients or partners in the target demographic
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Biogen, Inc.’s pipeline depth and focus of pipeline therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Table of Contents
List of Tables
List of Figures
Biogen, Inc. Snapshot
Biogen, Inc. Overview
Key Information
Key Facts
Biogen, Inc. - Research and Development Overview
Key Therapeutic Areas
Biogen, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Biogen, Inc. - Pipeline Products Glance
Biogen, Inc. - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Biogen, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Biogen, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Biogen, Inc. - Drug Profiles
coagulation factor IX (recombinant), Fc fusion protein
Product Description
Mechanism of Action
R&D Progress
rituximab
Product Description
Mechanism of Action
R&D Progress
aducanumab
Product Description
Mechanism of Action
R&D Progress
amiselimod hydrochloride
Product Description
Mechanism of Action
R&D Progress
BG-00011
Product Description
Mechanism of Action
R&D Progress
natalizumab
Product Description
Mechanism of Action
R&D Progress
opicinumab
Product Description
Mechanism of Action
R&D Progress
raxatrigine hydrochloride
Product Description
Mechanism of Action
R&D Progress
BG-00001
Product Description
Mechanism of Action
R&D Progress
BIIB-054
Product Description
Mechanism of Action
R&D Progress
BIIB-059
Product Description
Mechanism of Action
R&D Progress
BIIB-061
Product Description
Mechanism of Action
R&D Progress
BIIB-063
Product Description
Mechanism of Action
R&D Progress
dapirolizumab pegol
Product Description
Mechanism of Action
R&D Progress
5-D10
Product Description
Mechanism of Action
R&D Progress
CNV-1061436
Product Description
Mechanism of Action
R&D Progress
CNV-3000164
Product Description
Mechanism of Action
R&D Progress
CNV-3000223
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Hemophilia B
Product Description
Mechanism of Action
R&D Progress
NI-105
Product Description
Mechanism of Action
R&D Progress
NI-205
Product Description
Mechanism of Action
R&D Progress
PRT-2761
Product Description
Mechanism of Action
R&D Progress
Recombinant Interleukin-34 to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Replace Factor VIII for Hemophilia A
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize GPR-84 for Chronic Pain
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize P2Y14 for Osteoarthritic Pain
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit mPGES-1 for Chronic Pain
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Agonize ROR-Gamma for Autoimmune Disease
Product Description
Mechanism of Action
R&D Progress
Biogen, Inc. - Pipeline Analysis
Biogen, Inc. - Pipeline Products by Target
Biogen, Inc. - Pipeline Products by Route of Administration
Biogen, Inc. - Pipeline Products by Molecule Type
Biogen, Inc. - Pipeline Products by Mechanism of Action
Biogen, Inc. - Recent Pipeline Updates
Biogen, Inc. - Dormant Projects
Biogen, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
baminercept alfa
BG-00010
BIIB-023
clenoliximab
CNF-1010
dexpramipexole dihydrochloride
naxifylline
Biogen, Inc. - Company Statement
Biogen, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Biogen, Inc. - Key Manufacturing Facilities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Biogen, Inc., Key Information
Biogen, Inc., Key Facts
Biogen, Inc. - Pipeline by Indication, 2016
Biogen, Inc. - Pipeline by Stage of Development, 2016
Biogen, Inc. - Monotherapy Products in Pipeline, 2016
Biogen, Inc. - Partnered Products in Pipeline, 2016
Biogen, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
Biogen, Inc. - Out-Licensed Products in Pipeline, 2016
Biogen, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
Biogen, Inc. - Pre-Registration, 2016
Biogen, Inc. - Phase III, 2016
Biogen, Inc. - Phase II, 2016
Biogen, Inc. - Phase I, 2016
Biogen, Inc. - Preclinical, 2016
Biogen, Inc. - Discovery, 2016
Biogen, Inc. - Pipeline by Target, 2016
Biogen, Inc. - Pipeline by Route of Administration, 2016
Biogen, Inc. - Pipeline by Molecule Type, 2016
Biogen, Inc. - Pipeline Products by Mechanism of Action, 2016
Biogen, Inc. - Recent Pipeline Updates, 2016
Biogen, Inc. - Dormant Developmental Projects,2016
Biogen, Inc. - Discontinued Pipeline Products, 2016
Biogen, Inc., Other Locations
Biogen, Inc., Subsidiaries
Biogen, Inc., Key Manufacturing Facilities
List of Figures
Biogen, Inc. - Pipeline by Top 10 Indication, 2016
Biogen, Inc. - Pipeline by Stage of Development, 2016
Biogen, Inc. - Monotherapy Products in Pipeline, 2016
Biogen, Inc. - Partnered Products in Pipeline, 2016
Biogen, Inc. - Out-Licensed Products in Pipeline, 2016
Biogen, Inc. - Pipeline by Top 10 Target, 2016
Biogen, Inc. - Pipeline by Route of Administration, 2016
Biogen, Inc. - Pipeline by Molecule Type, 2016
Biogen, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report